Patents by Inventor Andrew S. Judd

Andrew S. Judd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS
    Publication number: 20250066388
    Abstract: The present invention provides for compounds of Formula (I) wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.
    Type: Application
    Filed: March 5, 2024
    Publication date: February 27, 2025
    Inventors: George A. Doherty, Vikram Bhat, Andrew S. Judd, Andrew J. Souers, Patrick Brady, Yujia Dai, Jianchun Gong, Yiyun Yu
  • ANTI-EGFR ANTIBODY DRUG CONJUGATES
    Publication number: 20240199745
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: July 10, 2023
    Publication date: June 20, 2024
    Inventors: Erwin R. Boghaert, Milan Bruncko, George Doherty, Robin R. Frey, Andrew S. Judd, Andrew C. Phillips, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao
  • 1,3,4,7-tetrahydro-2H-pyrrolo[3?,2?:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors
    Patent number: 11964990
    Abstract: The present invention provides for compounds of Formula (I) wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: April 23, 2024
    Assignee: AbbVie Inc.
    Inventors: George A. Doherty, Vikram Bhat, Andrew S. Judd, Andrew J. Souers
  • BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same
    Publication number: 20240058450
    Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
    Type: Application
    Filed: May 31, 2022
    Publication date: February 22, 2024
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors
    Publication number: 20230234971
    Abstract: The present invention provides for compounds of Formula (I) wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.
    Type: Application
    Filed: January 19, 2023
    Publication date: July 27, 2023
    Applicant: AbbVie Inc.
    Inventors: George A. Doherty, Vikram Bhat, Patrick Brady, Yujia Dai, Jianchun Gong, Andrew S. Judd, Andrew J. Souers, Yiyun Yu
  • Macrocyclic MCL-1 Inhibitors and Methods of Use
    Publication number: 20230183261
    Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: February 3, 2022
    Publication date: June 15, 2023
    Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Katja Jantos, Wilfried Braje, Andreas Kling, Frauke Pohlki, Thomas D. Penning
  • ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20230135723
    Abstract: The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 8, 2022
    Publication date: May 4, 2023
    Inventors: Lorenzo Benatuil, Milan Bruncko, Andrew S. Judd, Yingchun Li, Andrew Mccluskey, Andrew C. Phillips, Darren C. Phillips, Jane Seagal, Andrew J. Souers
  • ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20230120736
    Abstract: The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: April 27, 2022
    Publication date: April 20, 2023
    Inventors: Lorenzo Benatuil, Milan Bruncko, Andrew S. Judd, Yingchun Li, Andrew Mccluskey, Andrew C. Phillips, Darren C. Phillips, Jane Seagal, Andrew J. Souers
  • ANTI-EGFR ANTIBODY DRUG CONJUGATES
    Publication number: 20230114718
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: March 8, 2022
    Publication date: April 13, 2023
    Inventors: Erwin R. Boghaert, Milan Bruncko, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers
  • ANTI-EGFR ANTIBODY DRUG CONJUGATES
    Publication number: 20230077680
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: September 10, 2021
    Publication date: March 16, 2023
    Inventors: Erwin R. Boghaert, Milan Bruncko, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers
  • ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20210171637
    Abstract: The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: March 13, 2020
    Publication date: June 10, 2021
    Inventors: Lorenzo Benatuil, Debra Chao, Kamel Izeradjene, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers, Archana Thakur, Milan Bruncko
  • ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20200338209
    Abstract: The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: October 29, 2020
    Inventors: Lorenzo Benatuil, Milan Bruncko, Debra Chao, Kamel Izeradjene, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers, Archana Thakur
  • Macrocyclic MCL-1 Inhibitors and Methods of Use
    Publication number: 20200325153
    Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: May 11, 2020
    Publication date: October 15, 2020
    Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Katja Jantos, Wilfried Braje, Andreas Kling, Frauke Pohlki, Thomas D. Penning
  • BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same
    Publication number: 20200246460
    Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
    Type: Application
    Filed: September 6, 2019
    Publication date: August 6, 2020
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors
    Publication number: 20200246323
    Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
    Type: Application
    Filed: May 15, 2019
    Publication date: August 6, 2020
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Erwin R. Boghaert, Milan Bruncko, George Doherty, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-fu Tao, Xilu Wang, Dennle S. Welch
  • BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same
    Publication number: 20200239553
    Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
    Type: Application
    Filed: November 6, 2019
    Publication date: July 30, 2020
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • Macrocyclic MCL-1 inhibitors and methods of use
    Patent number: 10676485
    Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: June 9, 2020
    Assignee: AbbVie Inc.
    Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Zhi-Fu Tao, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Thomas D. Penning
  • ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20200147235
    Abstract: The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 8, 2017
    Publication date: May 14, 2020
    Inventors: Lorenzo Benatuil, Milan Bruncko, Andrew S. Judd, Yingchun Li, Andrew Mccluskey, Andrew C. Phillips, Darren C. Phillips, Jane Seagal, Andrew J. Souers
  • Anti-B7-H3 antibodies and antibody drug conjugates
    Patent number: 10640563
    Abstract: The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: May 5, 2020
    Assignee: AbbVie Inc.
    Inventors: Lorenzo Benatuil, Debra Chao, Kamel Izeradjene, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers, Archana Thakur
  • ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20200121803
    Abstract: The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 8, 2017
    Publication date: April 23, 2020
    Inventors: Lorenzo Benatuil, Milan Bruncko, Andrew S. Judd, Yingchun Li, Andrew Mccluskey, Andrew C. Phillips, Darren C. Phillips, Jane Seagal, Andrew J. Souers